Skip to content
Search

Latest Stories

'Hub and spoke must benefit patient care'

While responding to the consultation on hub and spoke dispensing, trade unions for pharmacists have emphasized that the patient safety and care must be the priority in hub and spoke dispensing.

The Royal Pharmaceutical Society (RPS) has welcomed the opportunity provided by a change in legislation to enable community pharmacies to make use of hub and spoke dispensing but reaffirmed that patient care must be at the heart of future changes.


With regards to patient safety, the Pharmaceutical Services Negotiating Committee (PSNC) considers that only Model 1 is appropriate, with manageable risks related to patient safety, and is a model that has the potential to allow the whole sector to benefit fairly.

In its response to the consultation on Hub and Spoke dispensing, PSNC highlighted that Model 2 in the consultation, a hub direct to patient supply of dispensed medicines, raises patient safety issues and it cannot be supported.

RPS President Professor Claire Anderson said: “In all models, patients need to continue to have access to a pharmacist at the time of supply of medicines so they have the opportunity to discuss, ask questions or raise concerns, and receive appropriate information with counselling and advice.

“Different hub and spoke models have been proposed in the consultation and it’s important that the models that are progressed provide benefits for patients and across the sector.

Claire stressed that new national guidance must be developed to clarify arrangements between hub and spoke, and this must be backed up by minimum regulatory standards and clear communications for the public.

“Resilience of the medicines supply chain also needs to be considered if purchasing, dispensing and distribution of medicines happens via a handful of hubs.”

PSNC added, “There are virtually no financial efficiencies envisaged by these - hub and spoke dispensing – proposals, and, if used, are more likely to add cost to the community pharmacy sector.”

“The value to the NHS and society of medicines supply through spoke pharmacies and the value to the public purse of community pharmacy purchasing of generic medicines should also be considered.”

More For You

Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less
Omega Pharmacy in Derbyshire Finds New Owner in Just 18 Days

Omega Pharmacy

Christie & Co

Omega Pharmacy in Derbyshire sold in just 18 days

Omega Pharmacy in Derbyshire has found a new owner in less than three weeks after being put on the market.

The pharmacy was previously owned by husband-and-wife duo Manny and Poonam Rai, who decided to sell it after a short period of ownership to focus on their other pharmacy in Coventry, according to Christie & Co.

Keep ReadingShow less
DHSC announces second list of March 2025 price concessions

A price concession only applies for the month it is granted.

Getty Images

March price concessions list released; prescription charge remains unchanged

The Department of Health and Social Care (DHSC) has released a second list of price concessions for March 2025, following ongoing discussions with Community Pharmacy England (CPE) regarding medicine pricing concerns raised by pharmacy owners.

A price concession is introduced when pharmacy contractors are unable to source a drug at or below the reimbursement price set out in the Drug Tariff.

Keep ReadingShow less
AstraZeneca partners with CEPI to develop multi-specific influenza antibody

AstraZeneca-CEPI collaboration aims to increase global access to antibody-based interventions

Getty Images

AstraZeneca secures £33M CEPI funding to develop multi-specific influenza antibody

AstraZeneca has joined forces with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance an innovative antibody technology that could help tackle future infectious disease outbreaks and pandemics swiftly and more affordably.

CEPI will provide up to US$43.5 million (£33.6 million) in funding to support the biopharmaceutical company in evaluating a type of antibody, known as a VHH (Variable Heavy domain of a Heavy chain -only antibody), through preclinical proof-of-concept studies and Phase 1 clinical trials.

Keep ReadingShow less